Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $78.4 million.

  • Nurix Therapeutics' Cash & Equivalents fell 20.80% to $78.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was $78.4 million, marking a year-over-year decrease of 20.80%. This contributed to the annual value of $110.0 million for FY2024, which is 101.36% up from last year.
  • According to the latest figures from Q3 2025, Nurix Therapeutics' Cash & Equivalents is $78.4 million, which was down 6.91% from $84.3 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Cash & Equivalents registered a high of $188.2 million during Q2 2021, and its lowest value of $33.6 million during Q1 2023.
  • In the last 3 years, Nurix Therapeutics' Cash & Equivalents had a median value of $75.9 million in 2025 and averaged $73.1 million.
  • Per our database at Business Quant, Nurix Therapeutics' Cash & Equivalents tumbled by 77.93% in 2022 and then surged by 134.12% in 2024.
  • Over the past 5 years, Nurix Therapeutics' Cash & Equivalents (Quarterly) stood at $80.5 million in 2021, then decreased by 19.91% to $64.5 million in 2022, then declined by 15.27% to $54.6 million in 2023, then skyrocketed by 101.36% to $110.0 million in 2024, then declined by 20.80% to $78.4 million in 2025.
  • Its last three reported values are $78.4 million in Q3 2025, $84.3 million for Q2 2025, and $75.9 million during Q1 2025.